CRT 23 Late-Breaking Science Video Collection

Published: 17 March 2023

  • Views:

    Views Icon 221
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

For short, concise coverage of the key data released at CRT 2023, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research. 

About the episode

CRT 23 - In this short interview from CRT's 2023 Scientific Sessions, we are joined by Dr Joost Daemen (Thoraxcenter, Erasmus University Medical Center, NL) to outline the FAST III Trial, sponsored by the European Cardiovascular Research Institute. In this study, over 2000 patients were randomized in a 1:1 manner, to vFFR or FFR guided revascularization for the treatment of coronary artery disease. Patients are followed up to 12 months, at which point, the primary endpoints of all-cause death, myocardial infarction and revascularization are analysed. 

Questions: 

  1. What was the rationale behind this study?
  2. What was the patient population, current enrollment status and study design?
  3. What is the potential impact of the results of this trial?
  4. What are the next steps for FAST III?

Recorded remotely from Rotterdam, 2023. 

Editor: Jordan Rance

Videography: Dan Brent

Faculty Biographies

Joost Daemen

Joost Daemen

Interventional Cardiologist

Dr Joost Daemen is a senior interventional cardiologist at the Thorax Center, Erasmus MC, Rotterdam, NL. Dr Daemen obtained his degree in medicine at the Erasmus University Medical Center. He is actively involved in several drug-eluting stent trials and is Principal Investigator of four trials focusing on the safety and efficacy of renal sympathetic denervation in hypertension, heart failure, vasospastic angina and heart failure. Dr Daemen is a member of the editorial board of EuroIntervention and the Netherlands Heart Journal, member of Young ICIN, and has completed courses in biomedical statistics and device training.

View full profile

Comments

You must be to comment. If you are not registered, you can register here.